Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor Next Article
DAPA-CKD trial shows extensive benefits of dapagliflozin »
« Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor Next Article
DAPA-CKD trial shows extensive benefits of dapagliflozin »
Related Articles
August 23, 2022
Talazoparib plus temozolomide appears efficacious in ES-SCLC
December 1, 2022
High retention rates after switching between infliximab biosimilars
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy